Black Hawk Acquisition Corporation BKHA
- Market cap
- $50.6M
- P/E
- —
Follow BKHA
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 10.09 | 10.38 | 11.00 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 10.46 | 11.95 | 13.10 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Black Hawk Acquisition Corporation peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| FTII FutureTech II Acquisition Corp. | $50.5M | 60.1× | Compare |
| ALCYF Alchemy Investments Acquisition Corp 1 | $49.7M | — | Compare |
| ALSAF Alpha Star Acquisition Corporation | $49.4M | 46.7× | Compare |
| EMCGF Embrace Change Acquisition Corp. | $53.6M | 56.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AOGO Arogo Capital Acquisition Corp. | $47.6M | 3.4× | Compare |
| YHNA YHN Acquisition I Limited | $47.6M | — | Compare |
| NBST Newbury Street Acquisition Corporation | $54.2M | 0.0× | Compare |
| CLRCF ClimateRock | $54.6M | 0.0× | Compare |
Black Hawk Acquisition Corporation (BKHA) Latest News
18 Mar
Vesicor Therapeutics appoints Michael Tolentino, M.D., as Chief Executive Officer. CEO appointment constitutes a major leadership shift that could significantly shape BKHA's strategic trajectory and market perception.
7 Jul
Black Hawk Acquisition Corporation has amended its definitive proxy statement, which outlines important details regarding its upcoming shareholder meeting and proposals. The amendments include updates to the voting procedures and additional information on the proposed business combination. Shareholders are encouraged to review the changes and participate in the voting process to influence the company's future direction. The amendments to the proxy statement may moderately influence shareholder decisions and the company's strategic direction.
20 Jun
Black Hawk Acquisition Corporation has amended its definitive proxy statement, which outlines important details regarding its upcoming shareholder meeting and proposals. The amendments include updates to the voting procedures and additional information on the proposed business combination. Shareholders are encouraged to review the changes and participate in the voting process to ensure their voices are heard regarding the future direction of the company. The amendments to the proxy statement may influence shareholder sentiment and voting outcomes, impacting the company's strategic direction.
28 Apr
Black Hawk Acquisition Corp. has signed a Business Combination Agreement with Vesicor Therapeutics, valuing Vesicor at a pre-money equity value of $70 million. The merger aims to create a biotechnology company focused on p53-based cancer therapeutics delivered via microvesicles. Vesicor's drug candidate, ecm-RV/p53, is currently unapproved in the U.S. but has been administered to patients in Japan. The transaction is expected to close in Q4 2025, pending regulatory and shareholder approvals. Vesicor's existing shareholders will roll over their equity into the combined company, which will be renamed Vesicor Therapeutics. The merger represents a significant strategic move that could enhance Black Hawk's market position and investor sentiment in the biotechnology sector.